PDCD1 and non-small cell lung carcinoma: Sato et al. found that in patients with NSCLC, anti-programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) monoclonal antibodies might impose procoagulant effects on the haemostatic system [38].